MLAB - Mesa Laboratories, Inc.
| Previous Close | 217.38 |
| Open | 218.29 |
| Bid | 180.00 x 800 |
| Ask | 275.00 x 800 |
| Day's Range | 218.06 - 222.45 |
| 52 Week Range | 167.34 - 268.47 |
| Volume | 78,813 |
| Avg. Volume | 110,538 |
| Market Cap | 864.711M |
| Beta (3Y Monthly) | 0.19 |
| PE Ratio (TTM) | 113.54 |
| EPS (TTM) | 1.94 |
| Earnings Date | Oct 29, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | 0.64 (0.25%) |
| Ex-Dividend Date | 2019-08-29 |
| 1y Target Est | 250.50 |
- GlobeNewswire
Mesa Laboratories, Inc. Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced the pricing of concurrent underwritten public offerings of (a) 375,000 shares of its common stock at a public offering price of $210.00 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $78.8 million and (b) $150 million aggregate principal amount of its 1.375% convertible senior notes due 2025 (the “notes”). In addition, Mesa has granted (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes. The offering of the shares is expected to result in approximately $73.9 million in net proceeds to Mesa after deducting underwriting discounts and commissions and other estimated offering expenses payable by Mesa (assuming no exercise of the underwriters’ option to purchase additional shares).
- GlobeNewswire
Mesa Laboratories, Inc. Announces Proposed Public Offering of Common Stock and Convertible Senior Notes
Mesa Laboratories, Inc. (MLAB) (“Mesa”) today announced that it has commenced concurrent underwritten public offerings of 375,000 shares of its common stock and $150 million aggregate principal amount of its convertible senior notes due 2025 (the “notes”). In addition, Mesa expects to grant (a) the underwriters of the common stock offering a 30-day option to purchase up to 56,250 additional shares and (b) the underwriters of the notes offering a 13-day option to purchase up to $22.5 million aggregate principal amount of additional notes.
- Simply Wall St.
Is Mesa Laboratories, Inc.'s (NASDAQ:MLAB) 6.6% ROE Worse Than Average?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Zacks
Mesa Labs (MLAB) Beats Q1 Earnings and Revenue Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of 7.18% and 2.29%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Mesa Labs Reports Record First Quarter Revenues and Adjusted Operating Income
LAKEWOOD, Colo., July 30, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record first quarter revenues and adjusted.
- Zacks
Earnings Preview: Mesa Labs (MLAB) Q1 Earnings Expected to Decline
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2019, to shareholders of record at the close of business on August 30, 2019. Mesa is a global technology innovator committed to solving some of the most critical quality control challenges in the pharmaceutical, healthcare, industrial safety, environmental and food and beverage industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring and Cold Chain Packaging) to help our customers ensure product integrity, increase patient and worker safety, and improve quality of life throughout the world.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Mesa Laboratories, Inc. (MLAB)
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of March. At Insider Monkey, we follow nearly 750 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
- PR Newswire
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent MarketAxess Holdings Inc. ...
- Simply Wall St.
Why You Should Like Mesa Laboratories, Inc.’s (NASDAQ:MLAB) ROCE
Today we'll look at Mesa Laboratories, Inc. (NASDAQ:MLAB) and reflect on its potential as an investment. Specifically...
- Associated Press
Mesa Labs: Fiscal 4Q Earnings Snapshot
The Lakewood, Colorado-based company said it had net income of 34 cents per share. Earnings, adjusted for stock option expense and amortization costs, were $1.75 per share. The quality control instruments ...
- GlobeNewswire
Mesa Labs Reports Record Revenues and Adjusted Operating Income for Fiscal Year 2019
LAKEWOOD, Colo., June 03, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record revenues and adjusted operating income1 for.
- Insider Monkey
Is Mesa Laboratories, Inc. (MLAB) A Good Stock To Buy?
"Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- Simply Wall St.
The Mesa Laboratories (NASDAQ:MLAB) Share Price Has Gained 204%, So Why Not Pay It Some Attention?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and...
- Simply Wall St.
Is Mesa Laboratories, Inc.’s (NASDAQ:MLAB) Balance Sheet Strong Enough To Weather A Storm?
While small-cap stocks, such as Mesa Laboratories, Inc. (NASDAQ:MLAB) with its market cap of US$913m, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...
- GlobeNewswire
Mesa Labs Announces Changes in The Composition of Its Board of Directors
LAKEWOOD, Colo., March 06, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) has announced several changes to the composition of its Board of.
- Simply Wall St.
Did Mesa Laboratories, Inc. (NASDAQ:MLAB) Use Debt To Deliver Its ROE Of 9.6%?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about theRead More...
- Zacks
Mesa Labs (MLAB) Misses Q3 Earnings Estimates
Mesa Labs (MLAB) delivered earnings and revenue surprises of -1.08% and 3.42%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Mesa Labs: Fiscal 3Q Earnings Snapshot
On a per-share basis, the Lakewood, Colorado-based company said it had net income of 21 cents. Earnings, adjusted for asset impairment costs and amortization costs, were $1.83 per share. The quality control ...
- GlobeNewswire
Mesa Labs Reports Record Third Quarter Revenues and Adjusted Operating Income
LAKEWOOD, Colo., Feb. 04, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today reported record revenues and adjusted operating income for.
- Zacks
Mesa Labs (MLAB) Earnings Expected to Grow: Should You Buy?
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Mesa's Board Announces Death of Board Member H. Stuart Campbell
Lakewood, Colo., Jan. 08, 2019 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that H. Stuart Campbell, Mesa’s Lead Independent.
- GlobeNewswire
Mesa Labs Declares Quarterly Dividend
Mesa Laboratories, Inc. (MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2019, to shareholders of record at the close of business on February 28, 2019. Mesa is a global technology innovator committed to solving some of the most critical quality control and analytical challenges in the pharmaceutical, healthcare, industrial safety, environmental and food & beverage industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring and Cold Chain Packaging) which help its customers ensure product integrity, increase patient and worker safety, and design innovative solutions that improve the quality of life throughout the world.
- Simply Wall St.
Are Insiders Selling Mesa Laboratories, Inc. (NASDAQ:MLAB) Stock?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
